Pgiam/iStock via Getty Images
CG Oncology (NASDAQ:CGON), a biotech focused on non-muscle invasive bladder cancer (NMIBC), traded ~9% higher on Wednesday after Guggenheim launched its coverage with a Buy recommendation and a $90 target, citing its prospects in the NMIBC market.
Analyst Brad Canino